Literature DB >> 19542720

[A case of marked response to CPT-11+CDDP neoadjuvant chemotherapy for advanced gastric cancer with paraaortic lymph node metastasis enabling curative resection and over 10-year survival].

Yozo Suzuki1, Yoshiaki Iwasaki, Manabu Ohashi, Souya Nunobe, Tomohiro Iwanaga, Keiichi Takahashi, Tatsurou Yamaguchi, Hiroshi Matsumoto, Daisuke Nakano, Tsunekazu Hishima.   

Abstract

We report a case of advanced gastric carcinoma successfully treated with a combination of irinotecan and cisplatin as neoadjuvant chemotherapy. The patient, a 51-year-old woman, had a type 2 gastric carcinoma, which had metastasized to paraaortic lymph nodes. She was treated with irinotecan, 70 mg on day 1 and day 15, and cisplatin, 80 mg on day 1. The course was repeated every 4 weeks. Two courses of treatment resulted in a marked reduction of both the primary tumor and lymph nodes. Subsequently, the patient underwent curative surgery consisting of pancreatoduodenectomy and D3 lymph node dissection. No surgical complication was observed. On microscopic examination, only a few tumor cells were detected in the granulation tissues of the lymph nodes, but viable cancer cells still remained in the resected stomach. This patient has been free of disease for more than 10 years after operation. This case demonstrates the effectiveness and safety of irinotecan and cisplatin used in an neoadjuvant setting for treatment of advanced gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542720

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.

Authors:  Salah-Eddin Al-Batran; Nils Homann; Claudia Pauligk; Gerald Illerhaus; Uwe M Martens; Jan Stoehlmacher; Harald Schmalenberg; Kim B Luley; Nicole Prasnikar; Matthias Egger; Stephan Probst; Helmut Messmann; Markus Moehler; Wolfgang Fischbach; Jörg T Hartmann; Frank Mayer; Heinz-Gert Höffkes; Michael Koenigsmann; Dirk Arnold; Thomas W Kraus; Kersten Grimm; Stefan Berkhoff; Stefan Post; Elke Jäger; Wolf Bechstein; Ulrich Ronellenfitsch; Stefan Mönig; Ralf D Hofheinz
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

2.  The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.

Authors:  Salah-Eddin Al-Batran; Thorsten O Goetze; Daniel W Mueller; Arndt Vogel; Michael Winkler; Sylvie Lorenzen; Alexander Novotny; Claudia Pauligk; Nils Homann; Thomas Jungbluth; Christoph Reissfelder; Karel Caca; Steffen Retter; Eva Horndasch; Julia Gumpp; Claus Bolling; Karl-Hermann Fuchs; Wolfgang Blau; Winfried Padberg; Michael Pohl; Andreas Wunsch; Patrick Michl; Frank Mannes; Matthias Schwarzbach; Harald Schmalenberg; Michael Hohaus; Christian Scholz; Christoph Benckert; Jorge Riera Knorrenschild; Veit Kanngießer; Thomas Zander; Hakan Alakus; Ralf-Dieter Hofheinz; Claus Roedel; Manish A Shah; Mitsuru Sasako; Dietmar Lorenz; Jakob Izbicki; Wolf O Bechstein; Hauke Lang; Stefan P Moenig
Journal:  BMC Cancer       Date:  2017-12-28       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.